Aurobindo Pharma pegfilgrastim biosimilar has received a major boost after the company’s wholly owned biosimilars subsidiary, CuraTeQ Biologics, secured regulatory clearance in Canada. Canadian health regulator, Health Canada has issued a Notice...
Teva Pharmaceuticals has signed a major funding agreement with Royalty Pharma worth up to $500 million, marking a significant boost for the development of TEV-408, its experimental anti-IL-15 antibody...
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyalur...
Eli Lilly’s Zepbound-Taltz combination has delivered strong results in a late-stage clinical trial, showing improved arthritis relief alongside meaningful weight loss, reinforcing the growing link between obesity management and inflammatory dis...
Gland Pharma USFDA approval marks a fresh milestone for the Hyderabad-based drugmaker, as it has received clearance from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Olopatadine Hydrochloride Ophthalmic S.
PharmNXT Biotech expands globally after acquiring Ireland’s DTR, adding GMP modular tubing tech to boost bioprocess efficiency, safety, and exports from India to Europe and Asia.
.jpeg "AiMeD Urges Govt to Raise Import Duty to Support MedTech Makers")
AiMeD urges the Centre to hike import tariffs to 10–15% in Budget 2026 to boost domestic medical device manufacturing, cut import dependence, and strengthen India’s MedTech ecosystem.
GSK has obtained a new prefilled syringe variant of Shingrix, which is an update to one of the most popular brands of shingles vaccines globally. The ruling paves the way to an improved presentation that will save time on preparation and...
The World Health Organization today released WHO HIV clinical guidelines that set a new direction for HIV treatment, prevention, and tuberculosis care, reflecting major scientific progress since the last update in 2021...
Shilpa Medicare Limited is preparing to seek US approval for its Ondansetron Extended-Release Injection (OERIS) within the next two years and is actively exploring licensing partners. The decision follows a successful Phase 3 trial in India, with..
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")